key: cord-0781275-rkgaug1j authors: Bogiatzopoulou, Aliki; Mayberry, Huw; Hawcutt, Daniel B.; Whittaker, Elizabeth; Munro, Alasdair; Roland, Damian; Simba, Justus; Gale, Christopher; Felsenstein, Susanna; Abrams, Elissa; Jones, Caroline B.; Lewins, Ian; Rodriguez-Martinez, Carlos R.; Fernandes, Ricardo M.; Stilwell, Philippa A.; Swann, Olivia; Bhopal, Sunil; Sinha, Ian; Harwood, Rachel title: COVID-19 in children: what did we learn from the first wave? date: 2020-09-18 journal: Paediatr Child Health (Oxford) DOI: 10.1016/j.paed.2020.09.005 sha: 1ff62fe34602f471c3201de932f18b5f9f09e4b1 doc_id: 781275 cord_uid: rkgaug1j A pandemic caused by the novel coronavirus, severe acute respiratory syndrome - coronavirus 2 (SARS-CoV-2), has caused high rates of mortality, predominantly in adults. Children are significantly less affected by SARS-CoV-2 with far lower rates of recorded infections in children compared to adults, milder symptoms in the majority of children and very low mortality rates. A suspected late manifestation of the disease, paediatric inflammatory multisystem syndrome - temporally associated with SARS-CoV-2 (PIMS-TS), has been seen in small numbers of children and has a more severe disease course than acute SARS-CoV-2. The pandemic has meant that children around the world have been kept off school, isolated from their extended family and friends and asked to stay inside. The UK has just been declared as being in an economic recession and unemployment rates are increasing. These indirect effects of SARS-CoV-2 are likely to have a significant impact on many children for years to come. Consolidating the knowledge that has accumulated during the first wave of this pandemic is essential for recognising the clinical signs, symptoms and effective treatment strategies for children; identifying children who may be at increased risk of severe SARS-CoV-2 infection; planning the safe delivery of healthcare and non-health related services that are important for childrens’ wellbeing; and engaging in, and developing, research to address the things that are not yet known. This article summarises the evidence that has emerged from the early phase of the pandemic and offers an overview for those looking after children or planning services. Severe Acute Respiratory Syndrome -Coronavirus 2 (SARS-CoV-2) has, up to the 10 th Aug, 2020, caused nearly 19.6 million infections and 727,000 deaths worldwide(1). This impact has largely been on adults. But what of children? Although not the face of the COVID-19 pandemic, they have been an important part of the story. Now is the time to what was learnt during the first wave, to prepare for any future wave(s) and to normalise the world for children as soon and safely as possible. With this in mind, we aim to discuss evidence, dilemmas, and theories, around COVID-19 in children. SARS-CoV-2 is a novel coronavirus, first isolated from patients with pneumonia in Wuhan, Coronaviruses take their name from spikes covering their surface, which aid entry into host cells. Using this spike-protein, SARS-CoV-2 interacts with Angiotensin Converting Enzyme 2 receptors (ACE2-r), expressed on the outer membrane of host cells in various tissues, particular alveolar epithelial cells, the endothelium and the intestinal epithelium(3). It is unclear what role, if any, the levels of soluble ACE2 play in host susceptibility to coronaviruses, and if ACE2 represents the only cell receptor used by SARS-CoV2. Worldwide, children constitute only 2% of recorded infections (4, 5) . When children have had contact with people infected with COVID-19 they are probably less likely to contract the infection compared to adults(6-8). Furthermore, they are far less likely to develop clinical symptoms, and severe illness is rare(9, 10). It is not yet clear why this is the case, particularly when viral respiratory illnesses typically affect children more severely and Influenza virus is associated with a more severe course (11) . The replication dynamics of SARS-CoV-2 are poorly described, but viral load in symptomatic patients is very high, and is higher in older patients (12) , which may in part account for the disease severity in the elderly. Children are also likely to have other viruses in their upper respiratory tract, and interactions and competition with SARS-CoV-2 may dampen its ability to cause infection (13) . ACE2-r may hold some of the answers. Like SARS-CoV-2, SARS-CoV uses the ACE2-r to enter cells and it has been shown that undifferentiated cells (which express lower levels of the ACE2-r) are less likely to be infected with the virus (14) . Children have significantly lower levels of ACE2-r than adults in their nasal epithelium (15) , and may make them less susceptible to infection. The immune system varies with age (16) , both in its composition and response to viruses. It is likely that the immune systems of babies, older children, and adults differ in response to J o u r n a l P r e -p r o o f SARS-CoV-2. Some differences might reflect the ability to protect against the virus, whereas others might relate to the more harmful effects of the immune response to infection. Previous exposure to seasonal coronavirus may also provide a level of protection through cross-reactive T-cell epitopes against SARS-CoV-2 (17) . Testing for COVID-19 can assess for either acute or previous infection, to detect early and late manifestations of the disease. For acute infection reverse transcriptase polymerase chain reaction (RT-PCR) is used, and is most accurate when performed on a nasopharyngeal sample. Factors that affect the accuracy of testing include the quality of sample, stage of disease, and viral load in the patient (18) . Overall, RT-PCR for SARS-CoV-2 has a high specificity of 95% but a lower sensitivity of approximately 70%(18). Depending on the type and timing of test, the sensitivity varies from 66% to 97.8%, and the specificity from 96.6% to 99.7% (19) . Knowing whether someone is currently or has recently been infected by COVID-19 is useful, but it does not determine whether someone who tests positive is shedding live virus. Whilst viral replication stops 5-7 days after the onset of symptoms, patients can remain RNApositive for up to a fortnight afterwards (20) . The results of the tests should therefore be taken within the context of the patient's presenting features and the community prevalence of COVID-19. The commonest acute presenting features in children with COVID-19 are fever, cough, lethargy, coryzal symptoms, and shortness of breath (10) . In the International Severe Acute Respiratory and emergency Infections Consortium WHO Clinical Characterisation Protocol UK (ISARIC WHO CCP-UK)) a distinct cluster of muco-enteric symptoms (including abdominal pain, vomiting, diarrhoea, conjunctivitis and rash) was also noted in the paediatric population (10) . Around 10% of hospitalised children with COVID-19 have an additional infective diagnosis such as urinary tract infection, appendicitis and sepsis (21) . Laboratory features of acute COVID-19 are variable and a significant proportion of children have normal investigations. Lymphopaenia, elevated inflammatory markers including C Reactive Protein (CRP) and procalcitonin have been documented but are by no means universal (22, 23) . Some Chinese children suspected of having COVID-19 underwent Computed Tomography (CT) of the thorax. The radiological findings of subpleural lesions were strongly associated with SARS-CoV-2 infection, along with more general findings consistent with viral infection (24) , but performing a CT did not alter the management of the majority of these children. When chest radiography has been performed in children with COVID-19 no specific features have been found to be diagnostic and therefore the indications for chest x-ray remain as they were before the pandemic. Children with COVID-19 who have radiological evidence of pneumonia are significantly more likely to require ICU admission. Very few neonates have been reported to have COVID-19. The majority who have been infected have not required intensive care unit (ICU) admission, although compared to all children, age under 1 month is a risk factor for ICU admission (25). Limited evidence suggests vertical transmission to neonates, whether intrauterine or perinatal, is possible but rare (26) and it is thought that the majority of infected neonates contracted COVID-19 after birth. Current literature does not suggest that SARS-CoV-2 can be transmitted through breast milk as no replicable virus has been identified(27). The World Health Organisation has concluded that mothers with suspected or confirmed COVID-19 should not be separated from their infants and that they should be encouraged to initiate and continue breastfeeding (28). Over 10% of children hospitalised with COVID-19 have contracted the virus whilst an inpatient (21) . This may reflect increased levels of testing within hospital compared to in the community but may also highlight children's increased susceptibility to infection during a hospital stay and requires further investigation. A North American Observational study of 48 children with COVID-19 who were admitted to ICU found that 86% had pre-existing comorbidities. These included being medically complex (40%), immunosuppressed (23%), obese (15%) and diabetic (8%). Thirty six percent of children in this series required J o u r n a l P r e -p r o o f mechanical ventilation and the association of respiratory support with co-morbidity is unclear (29) . It is likely that families with children with certain co-morbidities such as cancer have been actively shielding from an early stage, although early studies do not suggest that there is increased susceptibility to infection(30). Ongoing data collection about the impact of comorbidity on the rate and severity of COVID-19 should be continued. Most children with COVID-19 require only supportive therapy, with less than a quarter of hospitalised children requiring oxygen and very small numbers requiring ventilatory support Adult literature currently shows that the most effective agent for reducing mortality in critically unwell adults with acute COVID-19 is dexamethasone (32) . This reduces 28 day mortality in adults requiring oxygen by 20% and in adults requiring ventilation by 33%. It shows no benefit in adults who have not required either of these therapies. Remdesivir, an anti-viral treatment, has been shown to reduce time to clinical improvement in adults and is available for use in children (33). As respiratory compromise is relatively unusual with COVID-19 in children, its presence should trigger consideration of its cause. • COVID-19 pneumonia leads to patchy areas of consolidation, which reduce lung capacity. • High levels of inflammation are damaging to lung parenchyma, this inflammation in the longer term could lead to lung fibrosis (34). • COVID-19 infection is associated with anxiety (35). This can lead to tachypnoea, which in itself can be damaging to lungs and causes fatigue of respiratory muscles. • COVID-19 is a prothrombotic state (36), and in a child with disproportionately high oxygen requirement, a pulmonary embolism (or microthrombotic events) should be considered. PIMS-TS (Paediatric Inflammatory Multisystem Syndrome -Temporally Associated with SARS-CoV-2) is an emerging phenotype of illness that has been described in observational series from the UK, USA, Italy, France and Spain. Although definitions vary by country, the consistent features are inflammation and organ dysfunction in the absence of another explanation. Presentation can overlap with acute COVID-19 illness, or be a delayed response up to six weeks later (4, 7, 9) . The presentation of PIMS-TS is varied: some children present acutely unwell with features of shock, others with features consistent with complete or incomplete Kawasaki Disease, and others with more non-specific features (37) . Definitions, whether from the UK or US, include the presence of persistent fever at presentation. Abdominal pain is present in over 50% of children, along with hand and foot swelling, mucous membrane changes, nonpurulent conjunctivitis, rash and gastrointestinal disturbance (37) . A proposed list of investigations is presented in In common with Kawasaki's disease a significant proportion of children may develop coronary artery aneurysms, making follow-up echocardiography essential (38, 42) . Little is known about COVID-19 in Low and Middle Income Countries (LMICs) and issues with testing and reporting of cases has made tracking the spread and incidence of the disease difficult. At the time of writing, the African continent has reported 885,000 cases and 16,000 deaths with the majority of these in South Africa. India alone has reported 64,000 new cases in one day (43). The spread and severity of COVID-19 is expected be further exacerbated in LMICs by crowded living conditions, poor sanitation and difficult access to healthcare. The economic impact of enforced lockdown and social distancing has the potential to increase violence in areas already experiencing conflict, and violence against women and girls has been noted to increase since the beginning of the COVID-19 pandemic (44) . Food insecurity has been highlighted as a key area for concern by the World Bank (45). It is extremely likely that the negative impact of COVID-19 on children in LMICs will be much greater than the impact of the virus itself (46) . Lockdown causes deficiencies and inequity that may have a long-term effect on the wellbeing of children. It may particularly impact learning progress, socialising, friendship, play, romantic relationships and physical activity. In addition, children in lockdown experience an increase in both violence and addictive behaviours (e.g., junk food, alcohol, J o u r n a l P r e -p r o o f and other substances), and a decrease in positive factors related to health promotion (e.g., vaccination) (47, 48) . Concerns about the well-being of teenagers' mental health led to a review of child suicide rates during the pandemic. Whilst the numbers of deaths due to suicide were not statistically significantly increased compared to the previous year, themes around isolation and poor mental health were recognised as contributing factors for childhood suicide during the pandemic (49) . Some have argued there may be potential benefits for certain groups of children, including more time to share with family and appreciation of the value of social responsibility for the protection of the most vulnerable. However, for many, and particularly the most vulnerable children in our society, the balance of harms and benefits of a lockdown, and particularly school closure, clearly points away from this being a positive experience for many children. There are several key differences in the way research studies have been organised and delivered regarding COVID-19 and paediatrics. In the UK, the National Institute of Health The RECOVERY trial has been one of the most effective trials within the COVID-19 pandemic internationally. It has shown that hydroxychloroquine is ineffective (50) and that dexamethasone reduces mortality for individuals requiring oxygen, and particularly for ventilated patients (32) . Enrolling children whenever possible into trials for both COVID-19 and PIMS-TS is essential. We have already seen with both ISARIC and the RECOVERY trial the impact that rapidly mobilised, actively recruited trials can have on the knowledge and treatment of a new condition. Adaptations to the RECOVERY trial now means that children can be recruited to both phases, enabling high quality data collection within a trial whilst not removing the required multi-disciplinary team working that is essential for decision making about unwell children with severe acute COVID-19 and PIMS-TS. The COVID-19 pandemic is predicted to come in waves and the well-being of children must be prioritised and protected. They have sacrificed their social and educational development during the first wave, and going forward the focus must be on safely but actively returning them to normality. As paediatricians, we must be alert to cases of PIMS-TS, and other unusual presentations, and enrol children into appropriate research studies. Last and not least, we have a duty to keep up to date with published literature so we can provide care that is as evidence-based as possible when we are presented with children who may have COVID-19. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor The weekly surveillance report in England. Public Health England Children -United States Spread of SARS-CoV-2 in the Icelandic Population Epidemic Features, Hospital Outcomes, and Household Prevalence Suppression of COVID-19 outbreak in the municipality of Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study Clinical Characteristics of children and young people hospitalised with COVID-19 in the United Kingdom: prospective multicentre observational cohort study Comparison of hospitalized patients with pneumonia caused by COVID-19 and influenza A in children under 5 years Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. The Lancet Infectious Diseases Virusvirus interactions impact the population dynamics of influenza and the common cold ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults Evolution of the immune system in humans from infancy to old age Selective and crossreactive SARS-CoV-2 T cell epitopes in unexposed humans Interpreting a covid-19 test result Virological assessment of hospitalized patients with COVID-2019 COVID-19 -Service evaluation and audit on the care needs of children admitted to hospital Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. The Lancet Infectious Diseases Children with Covid-19 in Pediatric Emergency Departments in Italy The role of pulmonary CT scans for children during the COVID-19 pandemic COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. The Lancet Child & Adolescent Health Evaluation of SARS-CoV-2 in Breastmilk from 18 infected women. medRxiv. 2020. 28. WHO. Pregnancy, childbirth, breastfeeding and COVID-19 2020 Characteristics and Outcomes of Children With Coronavirus Disease Infection Admitted to US and Canadian Pediatric Intensive Care Units. JAMA Pediatr. 2020. 30 Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. The Lancet Respiratory Medicine Mood, anxiety and olfactory dysfunction in COVID-19: evidence of central nervous system involvement? Laryngoscope Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 A national consensus management pathway for Paediatric Inflammatory Multisystem Syndrome -Temporally associated with SARS-CoV-2 (PIMS-TS): The results of a national Delphi process Novel paediatric presentation of COVID-19 with ARDS and cytokine storm syndrome without respiratory symptoms Multisystem Inflammatory Syndrome in Children (MIS-C) Related to COVID-19: A New York City Experience Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. The Lancet Child & Adolescent Health Multisystem Inflammatory Syndrome in U.S. Children and Adolescents Impact of COVID-19 on VAWG in Nigeria. Department for Internatonal Development Food security and COVID-19 Is the effect of COVID-19 on children underestimated in low-and middle-income countries? Acta Paediatr. 2020. 47. Community-based health care, including outreach and campaigns The isolation period should be longer: Lesson from a child infected with SARS-CoV-2 in Chongqing Suicide Rates during the COVID-19 Pandemic in England: Real-time Surveillance Effect of Hydroxychloroquine in Hospitalised Patients with COVID-19: Preliminary results from a multi-centre, randomised controlled trial. medRxiv. 2020. Further reading Godfred COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. The Lancet Child & Adolescent Health Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report A national consensus management pathway for Paediatric Inflammatory Multisystem Syndrome -Temporally associated with SARS-CoV-2 (PIMS-TS): The results of a national Delphi process Clinical Characteristics of children and young people hospitalised with COVID-19 in the United Kingdom: prospective multicentre observational cohort study